DrugBiological
Bamlanivimab clinical trials
Also written LY3819253 and LY-CoV555.
- studies test it
- 12
- open now
- 0
- in phase 3
- 5
- first study started
- 2020
How studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2020 (9)
| Year | Studies |
|---|---|
| 2020 | 9 |
| 2021 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 5
- Phase 3
- 5
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 11
Who runs them
Industry 7 · Other 5
Eli Lilly and Company (6) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Daniel Griffin (1) · Sohail Rao (1) · Fraser Health (1)
Often tested with
Tested in the same studies.
Etesevimab (3) · Amubarvimab (2) · Romlusevimab (2) · Cilgavimab and tixagevimab drug combination (2) · Bebtelovimab (2) · Sotrovimab (2) · Interferon beta-1a (1) · Interferon Beta-1a Inhalation Solution SNG001 (1)
Studies
Open first, then newest update. How each study uses bamlanivimab is read from its arms, and is right about nine times in ten.
Testing it · 12
- ACTIV-2: A Study for Outpatients With COVID-19CompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT04518410Written as bamlanivimab 7000mg
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2/3Eli Lilly and CompanyNCT04427501Written as LY3819253
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780268Written as LY3819253
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as LY3819253
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2Eli Lilly and CompanyNCT04634409Written as Bamlanivimab
- Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized SettingStatus unknownPhase 2Sohail RaoNCT04840459Written as BAMLANIVIMAB
- At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19TerminatedPhase 4Daniel GriffinNCT04656691Written as bamlanivimab
- A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and StaffCompletedPhase 3Eli Lilly and CompanyNCT04497987Written as Bamlanivimab
- A Study of LY3819253 (LY-CoV555) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04537910Written as LY3819253
- A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)CompletedPhase 2Eli Lilly and CompanyNCT04701658Written as Bamlanivimab
- A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19CompletedPhase 1Eli Lilly and CompanyNCT04411628Written as LY3819253
- A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19Status unknownPhase 4Fraser HealthNCT04796402Written as Bamlanivimab
Codes
What other systems call bamlanivimab · ClinicalTrials.gg INT001473
- MeSH (NLM) C000711749bamlanivimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 45I6OFJ8QHBAMLANIVIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2463114Confirmed FDA, Wikidata
- Wikidata Q100391783bamlanivimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C173742BamlanivimabOne source FDA
- DrugBank DB15718One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711749 | bamlanivimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 45I6OFJ8QH | BAMLANIVIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2463114 | — | Confirmed FDA, Wikidata |
| Wikidata | Q100391783 | bamlanivimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C173742 | Bamlanivimab | One source FDA |
| DrugBank | DB15718 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.